Therapeutic drug monitoring for antimicrobial agents for people living with HIV (TAP) Article Swipe
Christine Sekaggya‐Wiltshire
,
Eva Agnes Laker Odongpiny
,
Francis Williams Ojara
,
Christine Sekaggya‐Wiltshire
,
Reuben Kiggundu
,
Hope Mackline
,
Catriona Waitt
,
Aida N. Kawuma
,
Allan Kengo
,
Allan Buzibye
,
Noela Owarwo
,
Francis Kakooza
,
Andrew Kambugu
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.12688/wellcomeopenres.22707.2
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.12688/wellcomeopenres.22707.2
Background Antimicrobial resistance (AMR) is a growing health concern, particularly in Africa, and is predicted to become the leading cause of death after cancer by 2050. Factors like overuse or inappropriate use of antibiotics contribute to this crisis. People living with HIV (PLWH) are particularly vulnerable to AMR with potential drug-drug interactions between antiretroviral and antimicrobial agents against common organisms like Mycobacterium tuberculosis. There is limited data on the concentrations of commonly used antimicrobial agents in people living with HIV in resource-limited settings. Therapeutic Drug Monitoring (TDM) offers a promising approach to optimize antibiotic dosing and improve treatment outcomes for those with sub-optimal drug concentrations. TDM has been recommended for PLWH on anti-tuberculosis treatment due to sub-optimal drug concentrations found in a significant proportion of those with TB. Objectives The main objectives of this study are to determine the concentrations of selected antimicrobial agents in people living with HIV requiring antimicrobial therapy and to assess the utility of therapeutic drug monitoring in achieving therapeutic targets for PLWH receiving rifampicin and isoniazid for the treatment of tuberculosis. Methods This prospective observational study will enroll adult PLWH receiving amoxicillin, azithromycin, ciprofloxacin, rifampicin, isoniazid, or ceftriaxone. Concentrations of these antibiotics will be measured locally using validated liquid chromatography mass spectrometry methods and high-performance liquid chromatography with ultraviolet detection. TDM with dose adjustment will be performed in a subset of participants on TB treatment. Pharmacokinetic parameters will be estimated using non-linear mixed effects models. Results This study was reviewed and approved by the research and ethics committee in February 2024. Participant enrolment began in September 2024. Conclusions We anticipate that the findings from this research will characterize pharmacokinetic and pharmacodynamics relationships to predict treatment response for optimal antimicrobial therapeutic and anti-tuberculosis dosing among people living with HIV (PLWH). Clinical registration The study is registered with Pan African Clinical Trials Registry, registration number PACTR202409710100607, registration date 07 August 2024, pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=31764
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.12688/wellcomeopenres.22707.2
- OA Status
- gold
- References
- 21
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4409660802
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4409660802Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.12688/wellcomeopenres.22707.2Digital Object Identifier
- Title
-
Therapeutic drug monitoring for antimicrobial agents for people living with HIV (TAP)Work title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-04-22Full publication date if available
- Authors
-
Christine Sekaggya‐Wiltshire, Eva Agnes Laker Odongpiny, Francis Williams Ojara, Christine Sekaggya‐Wiltshire, Reuben Kiggundu, Hope Mackline, Catriona Waitt, Aida N. Kawuma, Allan Kengo, Allan Buzibye, Noela Owarwo, Francis Kakooza, Andrew KambuguList of authors in order
- Landing page
-
https://doi.org/10.12688/wellcomeopenres.22707.2Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.12688/wellcomeopenres.22707.2Direct OA link when available
- Concepts
-
Medicine, Antimicrobial, Therapeutic drug monitoring, Tuberculosis, Rifampicin, Dosing, Drug, Antibiotics, Pharmacology, Intensive care medicine, Azithromycin, Microbiology, Biology, PathologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
21Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4409660802 |
|---|---|
| doi | https://doi.org/10.12688/wellcomeopenres.22707.2 |
| ids.doi | https://doi.org/10.12688/wellcomeopenres.22707.2 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40432826 |
| ids.openalex | https://openalex.org/W4409660802 |
| fwci | 0.0 |
| type | preprint |
| title | Therapeutic drug monitoring for antimicrobial agents for people living with HIV (TAP) |
| awards[0].id | https://openalex.org/G3188740802 |
| awards[0].funder_id | https://openalex.org/F4320311904 |
| awards[0].funder_award_id | 222075 |
| awards[0].funder_display_name | Wellcome Trust |
| biblio.issue | |
| biblio.volume | 9 |
| biblio.last_page | 694 |
| biblio.first_page | 694 |
| grants[0].funder | https://openalex.org/F4320311904 |
| grants[0].award_id | 222075 |
| grants[0].funder_display_name | Wellcome Trust |
| topics[0].id | https://openalex.org/T11036 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2736 |
| topics[0].subfield.display_name | Pharmacology |
| topics[0].display_name | Antibiotics Pharmacokinetics and Efficacy |
| topics[1].id | https://openalex.org/T10897 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9990000128746033 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2402 |
| topics[1].subfield.display_name | Applied Microbiology and Biotechnology |
| topics[1].display_name | Antibiotic Use and Resistance |
| topics[2].id | https://openalex.org/T12369 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9962999820709229 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2713 |
| topics[2].subfield.display_name | Epidemiology |
| topics[2].display_name | Pneumocystis jirovecii pneumonia detection and treatment |
| funders[0].id | https://openalex.org/F4320311904 |
| funders[0].ror | https://ror.org/029chgv08 |
| funders[0].display_name | Wellcome Trust |
| is_xpac | False |
| apc_list.value | 920 |
| apc_list.currency | GBP |
| apc_list.value_usd | 1128 |
| apc_paid.value | 920 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 1128 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.780846118927002 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C4937899 |
| concepts[1].level | 2 |
| concepts[1].score | 0.635670006275177 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q68541106 |
| concepts[1].display_name | Antimicrobial |
| concepts[2].id | https://openalex.org/C2780272996 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6168357729911804 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1261151 |
| concepts[2].display_name | Therapeutic drug monitoring |
| concepts[3].id | https://openalex.org/C2781069245 |
| concepts[3].level | 2 |
| concepts[3].score | 0.578560471534729 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q12204 |
| concepts[3].display_name | Tuberculosis |
| concepts[4].id | https://openalex.org/C2778607973 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5767002701759338 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q422652 |
| concepts[4].display_name | Rifampicin |
| concepts[5].id | https://openalex.org/C2777288759 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5102264881134033 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q4164182 |
| concepts[5].display_name | Dosing |
| concepts[6].id | https://openalex.org/C2780035454 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4970429241657257 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[6].display_name | Drug |
| concepts[7].id | https://openalex.org/C501593827 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4902186989784241 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[7].display_name | Antibiotics |
| concepts[8].id | https://openalex.org/C98274493 |
| concepts[8].level | 1 |
| concepts[8].score | 0.4744328558444977 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[8].display_name | Pharmacology |
| concepts[9].id | https://openalex.org/C177713679 |
| concepts[9].level | 1 |
| concepts[9].score | 0.44671109318733215 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[9].display_name | Intensive care medicine |
| concepts[10].id | https://openalex.org/C2778907293 |
| concepts[10].level | 3 |
| concepts[10].score | 0.41102659702301025 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q165399 |
| concepts[10].display_name | Azithromycin |
| concepts[11].id | https://openalex.org/C89423630 |
| concepts[11].level | 1 |
| concepts[11].score | 0.13191404938697815 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[11].display_name | Microbiology |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.0775783360004425 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| concepts[13].id | https://openalex.org/C142724271 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[13].display_name | Pathology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.780846118927002 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/antimicrobial |
| keywords[1].score | 0.635670006275177 |
| keywords[1].display_name | Antimicrobial |
| keywords[2].id | https://openalex.org/keywords/therapeutic-drug-monitoring |
| keywords[2].score | 0.6168357729911804 |
| keywords[2].display_name | Therapeutic drug monitoring |
| keywords[3].id | https://openalex.org/keywords/tuberculosis |
| keywords[3].score | 0.578560471534729 |
| keywords[3].display_name | Tuberculosis |
| keywords[4].id | https://openalex.org/keywords/rifampicin |
| keywords[4].score | 0.5767002701759338 |
| keywords[4].display_name | Rifampicin |
| keywords[5].id | https://openalex.org/keywords/dosing |
| keywords[5].score | 0.5102264881134033 |
| keywords[5].display_name | Dosing |
| keywords[6].id | https://openalex.org/keywords/drug |
| keywords[6].score | 0.4970429241657257 |
| keywords[6].display_name | Drug |
| keywords[7].id | https://openalex.org/keywords/antibiotics |
| keywords[7].score | 0.4902186989784241 |
| keywords[7].display_name | Antibiotics |
| keywords[8].id | https://openalex.org/keywords/pharmacology |
| keywords[8].score | 0.4744328558444977 |
| keywords[8].display_name | Pharmacology |
| keywords[9].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[9].score | 0.44671109318733215 |
| keywords[9].display_name | Intensive care medicine |
| keywords[10].id | https://openalex.org/keywords/azithromycin |
| keywords[10].score | 0.41102659702301025 |
| keywords[10].display_name | Azithromycin |
| keywords[11].id | https://openalex.org/keywords/microbiology |
| keywords[11].score | 0.13191404938697815 |
| keywords[11].display_name | Microbiology |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.0775783360004425 |
| keywords[12].display_name | Biology |
| language | en |
| locations[0].id | doi:10.12688/wellcomeopenres.22707.2 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210218052 |
| locations[0].source.issn | 2398-502X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2398-502X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Wellcome Open Research |
| locations[0].source.host_organization | https://openalex.org/P4310311838 |
| locations[0].source.host_organization_name | Wellcome |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311838 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Wellcome Open Research |
| locations[0].landing_page_url | https://doi.org/10.12688/wellcomeopenres.22707.2 |
| locations[1].id | pmid:40432826 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Wellcome open research |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40432826 |
| locations[2].id | pmh:oai:doaj.org/article:af106d995b8142f584478db96c38830d |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Wellcome Open Research, Vol 9 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/af106d995b8142f584478db96c38830d |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:12107230 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Wellcome Open Res |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12107230 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5036802370 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9247-2950 |
| authorships[0].author.display_name | Christine Sekaggya‐Wiltshire |
| authorships[0].countries | UG |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[0].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[0].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[0].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[0].institutions[0].type | nonprofit |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[0].institutions[0].country_code | UG |
| authorships[0].institutions[0].display_name | Infectious Diseases Institute |
| authorships[0].institutions[1].id | https://openalex.org/I72227227 |
| authorships[0].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[0].institutions[1].country_code | UG |
| authorships[0].institutions[1].display_name | Makerere University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Christine Sekaggya-Wiltshire |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[1].author.id | https://openalex.org/A5088522703 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Eva Agnes Laker Odongpiny |
| authorships[1].countries | UG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[1].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[1].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[1].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[1].institutions[0].type | nonprofit |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[1].institutions[0].country_code | UG |
| authorships[1].institutions[0].display_name | Infectious Diseases Institute |
| authorships[1].institutions[1].id | https://openalex.org/I72227227 |
| authorships[1].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[1].institutions[1].country_code | UG |
| authorships[1].institutions[1].display_name | Makerere University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Eva Agnes Laker Odongpiny |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[2].author.id | https://openalex.org/A5090953924 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6425-6828 |
| authorships[2].author.display_name | Francis Williams Ojara |
| authorships[2].countries | UG |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[2].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[2].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[2].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[2].institutions[0].type | nonprofit |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[2].institutions[0].country_code | UG |
| authorships[2].institutions[0].display_name | Infectious Diseases Institute |
| authorships[2].institutions[1].id | https://openalex.org/I72227227 |
| authorships[2].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[2].institutions[1].country_code | UG |
| authorships[2].institutions[1].display_name | Makerere University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Francis Williams Ojara |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[3].author.id | https://openalex.org/A5036802370 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9247-2950 |
| authorships[3].author.display_name | Christine Sekaggya‐Wiltshire |
| authorships[3].countries | UG |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[3].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[3].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[3].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[3].institutions[0].type | nonprofit |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[3].institutions[0].country_code | UG |
| authorships[3].institutions[0].display_name | Infectious Diseases Institute |
| authorships[3].institutions[1].id | https://openalex.org/I72227227 |
| authorships[3].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[3].institutions[1].country_code | UG |
| authorships[3].institutions[1].display_name | Makerere University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Isabella Kyohairwe |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[4].author.id | https://openalex.org/A5021821422 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6141-9436 |
| authorships[4].author.display_name | Reuben Kiggundu |
| authorships[4].countries | UG |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[4].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[4].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[4].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[4].institutions[0].type | nonprofit |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[4].institutions[0].country_code | UG |
| authorships[4].institutions[0].display_name | Infectious Diseases Institute |
| authorships[4].institutions[1].id | https://openalex.org/I72227227 |
| authorships[4].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[4].institutions[1].country_code | UG |
| authorships[4].institutions[1].display_name | Makerere University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Reuben Kiggundu |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[5].author.id | https://openalex.org/A5085795252 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-2593-8930 |
| authorships[5].author.display_name | Hope Mackline |
| authorships[5].countries | UG |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[5].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[5].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[5].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[5].institutions[0].type | nonprofit |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[5].institutions[0].country_code | UG |
| authorships[5].institutions[0].display_name | Infectious Diseases Institute |
| authorships[5].institutions[1].id | https://openalex.org/I72227227 |
| authorships[5].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[5].institutions[1].country_code | UG |
| authorships[5].institutions[1].display_name | Makerere University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Hope Mackline |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[6].author.id | https://openalex.org/A5081855852 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0134-5855 |
| authorships[6].author.display_name | Catriona Waitt |
| authorships[6].countries | GB, UG |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[6].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I146655781 |
| authorships[6].affiliations[1].raw_affiliation_string | University of Liverpool School of Medicine, Liverpool, England, UK. |
| authorships[6].institutions[0].id | https://openalex.org/I146655781 |
| authorships[6].institutions[0].ror | https://ror.org/04xs57h96 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I146655781 |
| authorships[6].institutions[0].country_code | GB |
| authorships[6].institutions[0].display_name | University of Liverpool |
| authorships[6].institutions[1].id | https://openalex.org/I4210116188 |
| authorships[6].institutions[1].ror | https://ror.org/02caa0269 |
| authorships[6].institutions[1].type | nonprofit |
| authorships[6].institutions[1].lineage | https://openalex.org/I4210116188 |
| authorships[6].institutions[1].country_code | UG |
| authorships[6].institutions[1].display_name | Infectious Diseases Institute |
| authorships[6].institutions[2].id | https://openalex.org/I72227227 |
| authorships[6].institutions[2].ror | https://ror.org/03dmz0111 |
| authorships[6].institutions[2].type | education |
| authorships[6].institutions[2].lineage | https://openalex.org/I72227227 |
| authorships[6].institutions[2].country_code | UG |
| authorships[6].institutions[2].display_name | Makerere University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Catriona Waitt |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda., University of Liverpool School of Medicine, Liverpool, England, UK. |
| authorships[7].author.id | https://openalex.org/A5069276558 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7975-0178 |
| authorships[7].author.display_name | Aida N. Kawuma |
| authorships[7].countries | UG |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[7].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[7].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[7].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[7].institutions[0].type | nonprofit |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[7].institutions[0].country_code | UG |
| authorships[7].institutions[0].display_name | Infectious Diseases Institute |
| authorships[7].institutions[1].id | https://openalex.org/I72227227 |
| authorships[7].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[7].institutions[1].country_code | UG |
| authorships[7].institutions[1].display_name | Makerere University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Aida N Kawuma |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[8].author.id | https://openalex.org/A5035390957 |
| authorships[8].author.orcid | https://orcid.org/0009-0000-5084-4314 |
| authorships[8].author.display_name | Allan Kengo |
| authorships[8].countries | UG |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[8].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[8].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[8].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[8].institutions[0].type | nonprofit |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[8].institutions[0].country_code | UG |
| authorships[8].institutions[0].display_name | Infectious Diseases Institute |
| authorships[8].institutions[1].id | https://openalex.org/I72227227 |
| authorships[8].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[8].institutions[1].country_code | UG |
| authorships[8].institutions[1].display_name | Makerere University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Allan Kengo |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[9].author.id | https://openalex.org/A5083300418 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-5874-3219 |
| authorships[9].author.display_name | Allan Buzibye |
| authorships[9].countries | UG |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[9].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[9].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[9].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[9].institutions[0].type | nonprofit |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[9].institutions[0].country_code | UG |
| authorships[9].institutions[0].display_name | Infectious Diseases Institute |
| authorships[9].institutions[1].id | https://openalex.org/I72227227 |
| authorships[9].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[9].institutions[1].type | education |
| authorships[9].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[9].institutions[1].country_code | UG |
| authorships[9].institutions[1].display_name | Makerere University |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Allan Buzibye |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[10].author.id | https://openalex.org/A5079514075 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-3455-2116 |
| authorships[10].author.display_name | Noela Owarwo |
| authorships[10].countries | UG |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[10].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[10].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[10].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[10].institutions[0].type | nonprofit |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[10].institutions[0].country_code | UG |
| authorships[10].institutions[0].display_name | Infectious Diseases Institute |
| authorships[10].institutions[1].id | https://openalex.org/I72227227 |
| authorships[10].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[10].institutions[1].type | education |
| authorships[10].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[10].institutions[1].country_code | UG |
| authorships[10].institutions[1].display_name | Makerere University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Noela Owarwo |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[11].author.id | https://openalex.org/A5057017327 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4047-6620 |
| authorships[11].author.display_name | Francis Kakooza |
| authorships[11].countries | UG |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[11].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[11].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[11].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[11].institutions[0].type | nonprofit |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[11].institutions[0].country_code | UG |
| authorships[11].institutions[0].display_name | Infectious Diseases Institute |
| authorships[11].institutions[1].id | https://openalex.org/I72227227 |
| authorships[11].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[11].institutions[1].type | education |
| authorships[11].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[11].institutions[1].country_code | UG |
| authorships[11].institutions[1].display_name | Makerere University |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Francis Kakooza |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[12].author.id | https://openalex.org/A5055903205 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-3075-0211 |
| authorships[12].author.display_name | Andrew Kambugu |
| authorships[12].countries | UG |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210116188, https://openalex.org/I72227227 |
| authorships[12].affiliations[0].raw_affiliation_string | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| authorships[12].institutions[0].id | https://openalex.org/I4210116188 |
| authorships[12].institutions[0].ror | https://ror.org/02caa0269 |
| authorships[12].institutions[0].type | nonprofit |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210116188 |
| authorships[12].institutions[0].country_code | UG |
| authorships[12].institutions[0].display_name | Infectious Diseases Institute |
| authorships[12].institutions[1].id | https://openalex.org/I72227227 |
| authorships[12].institutions[1].ror | https://ror.org/03dmz0111 |
| authorships[12].institutions[1].type | education |
| authorships[12].institutions[1].lineage | https://openalex.org/I72227227 |
| authorships[12].institutions[1].country_code | UG |
| authorships[12].institutions[1].display_name | Makerere University |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | Andrew Kambugu |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | College of Health Sciences, Makerere University Infectious Diseases Institute, Kampala, Central Region, Uganda. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.12688/wellcomeopenres.22707.2 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Therapeutic drug monitoring for antimicrobial agents for people living with HIV (TAP) |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11036 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2736 |
| primary_topic.subfield.display_name | Pharmacology |
| primary_topic.display_name | Antibiotics Pharmacokinetics and Efficacy |
| related_works | https://openalex.org/W4385771016, https://openalex.org/W2359342575, https://openalex.org/W2071510986, https://openalex.org/W2371062103, https://openalex.org/W2394487207, https://openalex.org/W2378244023, https://openalex.org/W2409208455, https://openalex.org/W4213414504, https://openalex.org/W2779877011, https://openalex.org/W4387571331 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.12688/wellcomeopenres.22707.2 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210218052 |
| best_oa_location.source.issn | 2398-502X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2398-502X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Wellcome Open Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310311838 |
| best_oa_location.source.host_organization_name | Wellcome |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311838 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Wellcome Open Research |
| best_oa_location.landing_page_url | https://doi.org/10.12688/wellcomeopenres.22707.2 |
| primary_location.id | doi:10.12688/wellcomeopenres.22707.2 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210218052 |
| primary_location.source.issn | 2398-502X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2398-502X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Wellcome Open Research |
| primary_location.source.host_organization | https://openalex.org/P4310311838 |
| primary_location.source.host_organization_name | Wellcome |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311838 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Wellcome Open Research |
| primary_location.landing_page_url | https://doi.org/10.12688/wellcomeopenres.22707.2 |
| publication_date | 2025-04-22 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4206677002, https://openalex.org/W3012503307, https://openalex.org/W4389388540, https://openalex.org/W2963372854, https://openalex.org/W2107834145, https://openalex.org/W2543303947, https://openalex.org/W3134024560, https://openalex.org/W2811190177, https://openalex.org/W2165195455, https://openalex.org/W3090487060, https://openalex.org/W3146080459, https://openalex.org/W4214501699, https://openalex.org/W4210586058, https://openalex.org/W4402348277, https://openalex.org/W4200175145, https://openalex.org/W2027951201, https://openalex.org/W2153424989, https://openalex.org/W4387728972, https://openalex.org/W2156273542, https://openalex.org/W2471913318, https://openalex.org/W2068357196 |
| referenced_works_count | 21 |
| abstract_inverted_index.a | 5, 88, 121, 223 |
| abstract_inverted_index.07 | 311 |
| abstract_inverted_index.TB | 228 |
| abstract_inverted_index.We | 263 |
| abstract_inverted_index.be | 198, 220, 233 |
| abstract_inverted_index.by | 24, 247 |
| abstract_inverted_index.in | 10, 75, 80, 120, 144, 161, 222, 253, 259 |
| abstract_inverted_index.is | 4, 13, 64, 298 |
| abstract_inverted_index.of | 20, 32, 70, 124, 132, 140, 157, 174, 194, 225 |
| abstract_inverted_index.on | 67, 111, 227 |
| abstract_inverted_index.or | 29, 191 |
| abstract_inverted_index.to | 15, 35, 46, 91, 115, 136, 153, 277 |
| abstract_inverted_index.AMR | 47 |
| abstract_inverted_index.HIV | 41, 79, 148, 292 |
| abstract_inverted_index.Pan | 301 |
| abstract_inverted_index.TB. | 127 |
| abstract_inverted_index.TDM | 105, 215 |
| abstract_inverted_index.The | 129, 296 |
| abstract_inverted_index.and | 12, 54, 95, 152, 169, 208, 245, 250, 274, 285 |
| abstract_inverted_index.are | 43, 135 |
| abstract_inverted_index.due | 114 |
| abstract_inverted_index.for | 99, 109, 165, 171, 281 |
| abstract_inverted_index.has | 106 |
| abstract_inverted_index.the | 17, 68, 138, 155, 172, 248, 266 |
| abstract_inverted_index.use | 31 |
| abstract_inverted_index.was | 243 |
| abstract_inverted_index.Drug | 84 |
| abstract_inverted_index.PLWH | 110, 166, 184 |
| abstract_inverted_index.This | 177, 241 |
| abstract_inverted_index.been | 107 |
| abstract_inverted_index.data | 66 |
| abstract_inverted_index.date | 310 |
| abstract_inverted_index.dose | 217 |
| abstract_inverted_index.drug | 103, 117, 159 |
| abstract_inverted_index.from | 268 |
| abstract_inverted_index.like | 27, 60 |
| abstract_inverted_index.main | 130 |
| abstract_inverted_index.mass | 205 |
| abstract_inverted_index.that | 265 |
| abstract_inverted_index.this | 36, 133, 269 |
| abstract_inverted_index.used | 72 |
| abstract_inverted_index.will | 181, 197, 219, 232, 271 |
| abstract_inverted_index.with | 40, 48, 78, 101, 126, 147, 212, 216, 291, 300 |
| abstract_inverted_index.(AMR) | 3 |
| abstract_inverted_index.(TDM) | 86 |
| abstract_inverted_index.2024, | 313 |
| abstract_inverted_index.2024. | 255, 261 |
| abstract_inverted_index.2050. | 25 |
| abstract_inverted_index.There | 63 |
| abstract_inverted_index.adult | 183 |
| abstract_inverted_index.after | 22 |
| abstract_inverted_index.among | 288 |
| abstract_inverted_index.began | 258 |
| abstract_inverted_index.cause | 19 |
| abstract_inverted_index.death | 21 |
| abstract_inverted_index.found | 119 |
| abstract_inverted_index.mixed | 237 |
| abstract_inverted_index.study | 134, 180, 242, 297 |
| abstract_inverted_index.these | 195 |
| abstract_inverted_index.those | 100, 125 |
| abstract_inverted_index.using | 201, 235 |
| abstract_inverted_index.(PLWH) | 42 |
| abstract_inverted_index.August | 312 |
| abstract_inverted_index.People | 38 |
| abstract_inverted_index.Trials | 304 |
| abstract_inverted_index.agents | 56, 74, 143 |
| abstract_inverted_index.assess | 154 |
| abstract_inverted_index.become | 16 |
| abstract_inverted_index.cancer | 23 |
| abstract_inverted_index.common | 58 |
| abstract_inverted_index.dosing | 94, 287 |
| abstract_inverted_index.enroll | 182 |
| abstract_inverted_index.ethics | 251 |
| abstract_inverted_index.health | 7 |
| abstract_inverted_index.liquid | 203, 210 |
| abstract_inverted_index.living | 39, 77, 146, 290 |
| abstract_inverted_index.number | 307 |
| abstract_inverted_index.offers | 87 |
| abstract_inverted_index.people | 76, 145, 289 |
| abstract_inverted_index.subset | 224 |
| abstract_inverted_index.(PLWH). | 293 |
| abstract_inverted_index.Africa, | 11 |
| abstract_inverted_index.African | 302 |
| abstract_inverted_index.Factors | 26 |
| abstract_inverted_index.Methods | 176 |
| abstract_inverted_index.Results | 240 |
| abstract_inverted_index.against | 57 |
| abstract_inverted_index.between | 52 |
| abstract_inverted_index.crisis. | 37 |
| abstract_inverted_index.effects | 238 |
| abstract_inverted_index.growing | 6 |
| abstract_inverted_index.improve | 96 |
| abstract_inverted_index.leading | 18 |
| abstract_inverted_index.limited | 65 |
| abstract_inverted_index.locally | 200 |
| abstract_inverted_index.methods | 207 |
| abstract_inverted_index.models. | 239 |
| abstract_inverted_index.optimal | 282 |
| abstract_inverted_index.overuse | 28 |
| abstract_inverted_index.predict | 278 |
| abstract_inverted_index.targets | 164 |
| abstract_inverted_index.therapy | 151 |
| abstract_inverted_index.utility | 156 |
| abstract_inverted_index.Clinical | 294, 303 |
| abstract_inverted_index.February | 254 |
| abstract_inverted_index.approach | 90 |
| abstract_inverted_index.approved | 246 |
| abstract_inverted_index.commonly | 71 |
| abstract_inverted_index.concern, | 8 |
| abstract_inverted_index.findings | 267 |
| abstract_inverted_index.measured | 199 |
| abstract_inverted_index.optimize | 92 |
| abstract_inverted_index.outcomes | 98 |
| abstract_inverted_index.research | 249, 270 |
| abstract_inverted_index.response | 280 |
| abstract_inverted_index.reviewed | 244 |
| abstract_inverted_index.selected | 141 |
| abstract_inverted_index.Registry, | 305 |
| abstract_inverted_index.September | 260 |
| abstract_inverted_index.achieving | 162 |
| abstract_inverted_index.committee | 252 |
| abstract_inverted_index.determine | 137 |
| abstract_inverted_index.drug-drug | 50 |
| abstract_inverted_index.enrolment | 257 |
| abstract_inverted_index.estimated | 234 |
| abstract_inverted_index.isoniazid | 170 |
| abstract_inverted_index.organisms | 59 |
| abstract_inverted_index.performed | 221 |
| abstract_inverted_index.potential | 49 |
| abstract_inverted_index.predicted | 14 |
| abstract_inverted_index.promising | 89 |
| abstract_inverted_index.receiving | 167, 185 |
| abstract_inverted_index.requiring | 149 |
| abstract_inverted_index.settings. | 82 |
| abstract_inverted_index.treatment | 97, 113, 173, 279 |
| abstract_inverted_index.validated | 202 |
| abstract_inverted_index.Monitoring | 85 |
| abstract_inverted_index.Objectives | 128 |
| abstract_inverted_index.adjustment | 218 |
| abstract_inverted_index.antibiotic | 93 |
| abstract_inverted_index.anticipate | 264 |
| abstract_inverted_index.contribute | 34 |
| abstract_inverted_index.detection. | 214 |
| abstract_inverted_index.isoniazid, | 190 |
| abstract_inverted_index.monitoring | 160 |
| abstract_inverted_index.non-linear | 236 |
| abstract_inverted_index.objectives | 131 |
| abstract_inverted_index.parameters | 231 |
| abstract_inverted_index.proportion | 123 |
| abstract_inverted_index.registered | 299 |
| abstract_inverted_index.resistance | 2 |
| abstract_inverted_index.rifampicin | 168 |
| abstract_inverted_index.treatment. | 229 |
| abstract_inverted_index.vulnerable | 45 |
| abstract_inverted_index.Conclusions | 262 |
| abstract_inverted_index.Participant | 256 |
| abstract_inverted_index.Therapeutic | 83 |
| abstract_inverted_index.antibiotics | 33, 196 |
| abstract_inverted_index.prospective | 178 |
| abstract_inverted_index.recommended | 108 |
| abstract_inverted_index.rifampicin, | 189 |
| abstract_inverted_index.significant | 122 |
| abstract_inverted_index.sub-optimal | 102, 116 |
| abstract_inverted_index.therapeutic | 158, 163, 284 |
| abstract_inverted_index.ultraviolet | 213 |
| abstract_inverted_index.amoxicillin, | 186 |
| abstract_inverted_index.ceftriaxone. | 192 |
| abstract_inverted_index.characterize | 272 |
| abstract_inverted_index.interactions | 51 |
| abstract_inverted_index.participants | 226 |
| abstract_inverted_index.particularly | 9, 44 |
| abstract_inverted_index.registration | 295, 306, 309 |
| abstract_inverted_index.spectrometry | 206 |
| abstract_inverted_index.<ns5:ext-link | 314 |
| abstract_inverted_index.Antimicrobial | 1 |
| abstract_inverted_index.antimicrobial | 55, 73, 142, 150, 283 |
| abstract_inverted_index.azithromycin, | 187 |
| abstract_inverted_index.inappropriate | 30 |
| abstract_inverted_index.observational | 179 |
| abstract_inverted_index.relationships | 276 |
| abstract_inverted_index.tuberculosis. | 175 |
| abstract_inverted_index.Concentrations | 193 |
| abstract_inverted_index.antiretroviral | 53 |
| abstract_inverted_index.chromatography | 204, 211 |
| abstract_inverted_index.ciprofloxacin, | 188 |
| abstract_inverted_index.concentrations | 69, 118, 139 |
| abstract_inverted_index.Pharmacokinetic | 230 |
| abstract_inverted_index.concentrations. | 104 |
| abstract_inverted_index.pharmacokinetic | 273 |
| abstract_inverted_index.high-performance | 209 |
| abstract_inverted_index.pharmacodynamics | 275 |
| abstract_inverted_index.resource-limited | 81 |
| abstract_inverted_index.<ns5:p>Background | 0 |
| abstract_inverted_index.anti-tuberculosis | 112, 286 |
| abstract_inverted_index.ext-link-type="uri" | 316 |
| abstract_inverted_index.PACTR202409710100607, | 308 |
| abstract_inverted_index.<ns5:italic>Mycobacterium | 61 |
| abstract_inverted_index.tuberculosis.</ns5:italic> | 62 |
| abstract_inverted_index.xmlns:ns6="http://www.w3.org/1999/xlink" | 315 |
| abstract_inverted_index.ns6:href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=31764">pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=31764</ns5:ext-link></ns5:p> | 317 |
| cited_by_percentile_year | |
| countries_distinct_count | 2 |
| institutions_distinct_count | 13 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.75 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.15348876 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |